Clinical Trial Update: Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 diagnostic trial evaluates a fully hybrid 18F-PSMA PET/MRI approach as a one-stop method to diagnose clinically significant prostate cancer; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA (fluorine-18 labeled PSMA radiotracer)

Snippet

Sponsor: IRCCS San Raffaele | Conditions: Clinical Suspicion of Prostate Cancer | Phase 2 | Status: RECRUITING